Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2026-06-02 17:31:54 ET · period of report 2026-06-01 · accession 0001628280-26-039938 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-02 17:31 | 2026-06-01 | VIR | Sabatini Brent | SVP, CAO | S - Sale | $9.45 | -379 | 61.9K | -0.6% | -$3,582 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-01 | S | D | 379 | $9.45 | 61,902 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. (F2) Includes 379 shares of common stock acquired by the Reporting Person on May 29, 2026 pursuant to an employee stock purchase program. |